This company has been acquired
La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
SCTL Aperçu des actions
Societal CDMO, Inc., a contract development and manufacturing organization, engages in the research and development, manufacturing, and packaging for various therapeutic dosage forms primarily in the small molecules in the United States and internationally.
| Score flocon de neige | |
|---|---|
| Évaluation | 3/6 |
| Croissance future | 1/6 |
| Performances passées | 0/6 |
| Santé financière | 3/6 |
| Dividendes | 0/6 |
Récompenses
Analyse des risques
+ 1 plus de risques
Societal CDMO, Inc. Concurrents
Historique des prix et performances
| Historique des cours de bourse | |
|---|---|
| Prix actuel de l'action | US$1.10 |
| Plus haut sur 52 semaines | US$1.28 |
| Plus bas sur 52 semaines | US$0.26 |
| Bêta | 1.52 |
| 1Variation sur 1 mois | 1.85% |
| Variation sur 3 mois | 181.33% |
| Variation sur 1 an | 4.76% |
| 3Variation sur 3 ans | -65.52% |
| Variation sur 5 ans | -86.89% |
| Évolution depuis l'introduction en bourse | -86.75% |
Nouvelles et mises à jour récentes
Recent updates
Societal CDMO, Inc.'s (NASDAQ:SCTL) Price Is Right But Growth Is Lacking After Shares Rocket 38%
Feb 10
Is There An Opportunity With Societal CDMO, Inc.'s (NASDAQ:SCTL) 46% Undervaluation?
Feb 02Is Societal CDMO (NASDAQ:SCTL) Weighed On By Its Debt Load?
Dec 23Does Societal CDMO (NASDAQ:SCTL) Have A Healthy Balance Sheet?
May 31Societal CDMO signs two CDMO service agreements
Oct 20Societal stock soars 20% on signing 2 manufacturing contracts
Sep 07Societal CDMO estimates to receive up to $50M on real estates' sales
Aug 16Societal CDMO, Lannett amend license and supply deal
Jul 12These 4 Measures Indicate That Societal CDMO (NASDAQ:SCTL) Is Using Debt Extensively
Apr 29Is Recro Pharma (NASDAQ:REPH) A Risky Investment?
Jan 06Recro Pharma jumps 15% on Q1 result estimates beat
May 07Would Shareholders Who Purchased Recro Pharma's (NASDAQ:REPH) Stock Year Be Happy With The Share price Today?
Feb 15
Rendement pour les actionnaires
| SCTL | US Pharmaceuticals | US Marché | |
|---|---|---|---|
| 7D | 0% | -2.7% | 0.9% |
| 1Y | 4.8% | 21.0% | 32.3% |
Rendement vs Industrie: SCTL underperformed the US Pharmaceuticals industry which returned 16.6% over the past year.
Rendement vs marché: SCTL underperformed the US Market which returned 25.9% over the past year.
Volatilité des prix
| SCTL volatility | |
|---|---|
| SCTL Average Weekly Movement | 39.2% |
| Pharmaceuticals Industry Average Movement | 9.7% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 14.8% |
| 10% least volatile stocks in US Market | 3.2% |
Cours de l'action stable: SCTL's share price has been volatile over the past 3 months.
Volatilité au fil du temps: SCTL's weekly volatility has increased from 23% to 39% over the past year.
À propos de l'entreprise
| Fondée | Salariés | PDG | Site web |
|---|---|---|---|
| 2007 | 258 | J. Enloe | www.societalcdmo.com |
Societal CDMO, Inc. Résumé des fondamentaux
| SCTL statistiques fondamentales | |
|---|---|
| Capitalisation boursière | US$116.26m |
| Bénéfices(TTM) | -US$13.27m |
| Recettes(TTM) | US$94.64m |
1.2x
Ratio P/S-8.8x
Ratio P/ELe site SCTL est-il surévalué ?
Voir Juste valeur et analyse de l'évaluationBénéfices et recettes
| SCTL compte de résultat (TTM) | |
|---|---|
| Recettes | US$94.64m |
| Coût des recettes | US$76.50m |
| Marge brute | US$18.14m |
| Autres dépenses | US$31.41m |
| Les revenus | -US$13.27m |
Derniers bénéfices déclarés
Dec 31, 2023
Prochaine date de publication des résultats
s/o
| Résultat par action (EPS) | -0.13 |
| Marge brute | 19.17% |
| Marge bénéficiaire nette | -14.03% |
| Ratio dettes/capitaux propres | 63.2% |
Quelles ont été les performances à long terme de SCTL?
Voir les performances historiques et les comparaisons